Pharmacological treatments for basal cell carcinoma

Drugs

Volumn 67, Issue 6, 2007, Pages 915-934

  Lee, Seongmu ^a   Selva, Dinesh ^b,c   Huilgol, Shyamala C ^b   Goldberg, Robert A ^a   Leibovitch, Igal ^a,b  

^a JULES STEIN EYE INSTITUTE   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c South Australian Institute of Ophthalmology   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ALKALOID DERIVATIVE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMINOLAEVULINIC ACID; ANTINEOPLASTIC AGENT; BLEOMYCIN; CELECOXIB; CIDOFOVIR; DOBESILATE CALCIUM; FLUOROURACIL; GLYCOALKALOID; IMIQUIMOD; INTERFERON; METHYLAMINOLAEVULINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHOTOFRIN; PHOTOSENSITIZING AGENT; PLACEBO; RECOMBINANT ALPHA INTERFERON; TAZAROTENE; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ANGIONEUROTIC EDEMA; APPLCIATION SITE STINGING; APPLICATION SITE BURNING; APPLICATION SITE DISCHARGE; APPLICATION SITE DISCOMFORT; APPLICATION SITE ERYTHEMA; APPLICATION SITE HYPERPIGMENTATION; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; APPLICATION SITE REACTION; APPLICATION SITE SCABBING; APPLICATION SITE STINGING; APPLICATION SITE ULCER; BASAL CELL CARCINOMA; BULLOUS PEMPHIGOID; CANCER RECURRENCE; CANCER RISK; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CRUSTING; CRYOTHERAPY; CURETTAGE; DESICCATION; DESQUAMATION; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ELECTRODE; EROSION; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; HYPERTHERMIA; HYPERTROPHIC SCAR; HYPOPIGMENTATION; INJECTION SITE DISCOMFORT; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LEAKAGE; LEUKOPENIA; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PAIN; PAPULAR RASH; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SKIN EDEMA; SKIN INDURATION; SKIN IRRITATION; SKIN MANIFESTATION; SKIN PIGMENTATION; SKIN ULCER; THROMBOCYTOPENIA; TISSUE PRESERVATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 34247274811     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767060-00007     Document Type: Review

References (167)

1. American Cancer Society. Cancer facts and figures [online]. Available from URL: http://www.cancer.org/docroot/STT/stt_0.asp [Accessed 2006 April]
2. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005; 353 (21): 2262-9
3. Canadian Cancer Society. Canadian cancer statistics 2006 [online]. Available from URL: http://129.33.170.32/ccs/internet/standard/0,3182, 3172_14279__langId-en,00.html [Accessed 2007 Feb]
4. Green A, Battistutta D, Hart V, et al. Skin cancer in a subtropical Australian population: incidence and lack of association with occupation. Am J Epidemiol 1996; 144 (11): 1034-40
5. Buettner PG, Raasch BA. Incidence rates of skin cancer in Townsville, Australia. Int J Cancer 1998; 78 (5): 587-93
6. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146 Suppl. 61: 1-6
7. Wong CSM, Strange RC, Lear JT. Basal cell carcinoma. BMJ 2003; 327 (7418): 794-8
8. de Vries E, Louwman M, Bastiaens M, et al. Rapid and continuous increases in incidence rates of basal cell carcinoma in the southeast Netherlands since 1973. J Invest Dermatol 2004; 123 (4): 634-8
9. Holme SA, Malinovszky K, Roberts DL. Changing trends in non-melanoma skin cancer in South Wales, 1988-98. Br J Dermatol 2000; 143 (6): 1224-9
10. Preston DS, Stern, RS: Nonmelanoma cancers of the skin. N Engl J Med 1992; 327 (23): 1649-62
11. Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005; 294 (6): 681-90
12. Wrone DA, Swetter SM, Egbert BM, et al. Increased proportion of aggressive-growth basal cell carcinoma in the Veterans Affairs population of Palo Alto, California. J Am Acad Dermatol 1996; 35 (6): 907-10
13. Saldanha G, Fletcher A, Slater DN. Basal cell carcinoma: a dermatopathological and molecular biological update. Br J Dermatol 2003; 148 (2): 195-202
14. Rippey JJ. Why classify basal cell carcinomas? Histopathology 1998; 32 (5): 393-8
15. National Comprehensive Cancer Network. Clinical practice guidelines in oncology v.1.2007. Basal cell skin cancer [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/nmsc.pdf [Accessed 2007 Feb 5]
16. Silverman MK, Kopf AW, Bart RS, et al. Recurrence rates of treated basal cell carcinomas: part 3. Surgical excision. J Dermatol Surg Oncol 1992; 18 (6): 471-6
17. Griffiths RW, Suvarna SK, Stone J. Do basal cell carcinomas recur after complete conventional surgical excision? Br J Plast Surg 2005; 58 (6): 795-805
18. Smeets NW, Krekels GA, Ostertag JU, et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 2004; 364 (9447): 1766-72
19. Bart RS, Schrager D, Kopf AW, et al. Scalpel excision of basal cell carcinomas. Arch Dermatol 1978; 114 (5): 739-42
20. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15 (3): 315-28
21. Nagore E, Grau C, Molinero J, et al. Positive margins in basal cell carcinoma: relationship to clinical features and recurrence risk: a retrospective study of 248 patients. J Eur Acad Dermatol Venereol 2003; 17 (2): 167-70
22. Leibovitch I, Huilgol SC, Selva D, et al. Basal cell carcinoma treated with Mohs surgery in Australia: II. Outcome at 5-year follow-up. J Am Acad Dermatol 2005; 53 (3): 452-7
23. Smeets NW, Kuijpers DI, Nelemans P, et al. Mohs' micrographic surgery for treatment of basal cell carcinoma of the face: results of a retrospective study and review of the literature. Br J Dermatol 2004; 151 (1): 141-7
24. Mundt AJ, Roeske JC, Weichelbaum RR. Principles of radiation oncology. In Bast RC Jr, Kuff DW, Pollock RE, et al., editors. Cancer Medicine, 5th ed. Hamilton, ON: BC Decker Inc., 2000
25. Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys 2004; 60 (2): 406-11
26. Locke J, Karimpour S, Young G, et al. Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys 2001; 51 (3): 748-55
27. Carcinoma of the skin. In: American Joint Committee on Cancer. AJCC Cancer Staging Manual, 6th ed. New York (NY): Springer, 2002: 203-8
28. Wilder RB, Kittelson JM, Shimm DS. Basal cell carcinoma treated with radiation therapy. Cancer 1991; 68 (10): 2134-7
29. Wilder RB, Shimm DS, Kittelson JM, et al. Recurrent basal cell carcinoma treated with radiation therapy. Arch Dermatol 1991; 127 (11): 1668-72
30. Silverman MK, Kopf AW, Gladstein AH, et al. Recurrence rates of treated basal cell carcinomas: part 4. X-ray therapy. J Dermatol Surg Oncol 1992; 18 (7): 549-54
31. Lovett RD, Perez CA, Shapiro SJ, et al. External irradiation of epithelial skin cancer. Int J Radiat Oncol Biol Phys 1990; 19 (2): 235-42
32. Griep C, Davelaar J, Scholten AN, et al. Electron beam therapy is not inferior to superficial x-ray therapy in the treatment of skin carcinoma. Int J Radiat Oncol Biol Phys 1995; 32 (5): 1347-50
33. Petit JY, Avril MF, Margulis A, et al. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg 2000; 105 (7): 2544-51
34. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000; 43 (1 Pt 2): S6-11
35. Imiquimod 5% cream [online]. Available from URL: http://www.fda.gov/ medwatch/safety/2005/aug_PI/Aldara_PI.pdf [Accessed 2006 April]
36. Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003; 139 (10): 1325-32
37. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114 (1): 135-41
38. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1 (2): 135-45
39. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3 (2): 196-200
40. Arany I, Tyring SK, Stanley MA, et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res 1999; 43 (1): 55-63
41. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002; 27 (7): 571-7
42. Vidal D, Matias-Guiu X, Alomar A. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br J Dermatol 2004; 151 (3): 656-62
43. Schon M, Bong AB, Drewiniok C. Tumor-selective induction of apoptosis and the small-molecule immune modifier imiquimod. J Natl Cancer Inst 2003; 95 (15): 1138-49
44. Berman B, Sullivan T, De Araujo T, et al. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 2003; 149 Suppl. 66: 59-61
45. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50 (5): 722-33
46. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152 (5): 939-47
47. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47 (3): 390-8
48. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41 (6): 1002-7
49. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002; 138 (9): 1165-71
50. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147 (6): 1227-36
51. Shumack S, Gebauer K, Quirk C, et al. 5% Imiquimod cream for the treatment of large superficial basal cell carcinoma. Arch Dermatol 2004; 140 (10): 1286-7
52. Wu JK, Oh C, Strutton G, et al. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol 2006; 47 (1): 46-8
53. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg 2006; 32 (1): 63-9
54. Peris K, Campione E, Micantonio T, et al. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005; 31 (3): 318-23
55. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol 2005; 15 (5): 374-81
56. Quirk C, Gebauer K, Owens M, et al. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Aust J Dermatol 2006; 47 (4): 258-65
57. Aldara prescribing insert. 3M Pharmaceuticals, August 2005
58. Harrison LI, Skinner SL, Marbury TC, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res 2004; 296 (1): 6-11
59. Owens ML, Bridson WE, Smith SL, et al. Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and perianal warts [abstract]. Prim Care Update Obs Gyn 1998; 5 (4): 151
60. Hanger C, Dalrymple J, Hepburn D. Systemic side effects from topical imiquimod. N Z Med J 2005; 118 (1223): U1682
61. Systemic reactions to imiquimod (Aldara). Med Lett Drugs Ther 2004; 46 (1195): 92
62. Barton JC. Angioedema associated with imiquimod. J Am Acad Dermatol 2004; 51 (3): 477-8
63. Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004; 140 (12): 1490-5
64. Rajan N, Langtry JA. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin Exp Dermatol 2006; 31 (1): 140-1
65. Marks R, Owens M, Walters SA, et al. Efficacy and safety of 5% imiquimod cream in treating patients with multiple superficial basal cell carcinomas. Arch Dermatol 2004; 140 (10): 1284-5
66. Torres A, Niemeyer A, Berkes B, et al. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. Dermatol Surg 2004; 30 (12 Pt 1): 1462-9
67. Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2001
68. Ransohoff RM. Cellular responses to interferons and other cytokines: the JAK-STAT paradigm. N Engl J Med 1998; 338 (9): 616-8
69. Eisenbeis CF, Lesinski GB, Anghelina M, et al. Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol 2005; 23 (34): 8835-44
70. Liu KD, Gaffen SL, Goldsmith MA. JAK/STAT signaling by cytokine receptors. Curr Opin Immunol 1998; 10 (3): 271-8
71. Orange JS, Biron CA. Characterization of early IL-12, IFN-alphabeta, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. J Immunol 1996; 156 (12): 4746-56
72. Biron C. Interferons alpha and beta as immune regulators: a new look. Immunity 2001; 14 (6): 661-4
73. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14 (4): 778-809
74. Der SD, Zhou A, Williams BR, et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998; 95 (26): 15623-8
75. Tompkins WA. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res 1999; 19 (8): 817-28
76. Buechner S, Wernli M, Bachmann F, et al. Intralesional interferon in basal cell carcinoma: how does it work? Recent Results Cancer Res 2002; 160: 246-50
77. Buechner SA, Wernli M, Harr T, et al. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J Clin Invest 1997; 100 (11): 2691-6
78. Li C, Chi S, He N, et al. IFNalpha induces Fas expression and apoptosis in hedgehog pathway activated BCC cells through inhibiting Ras-Erk signaling. Oncogene 2004; 23 (8): 1608-17
79. Kowalzick L, Rogozinski T, Wimheuer R, et al. Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study. Eur J Dermatol 2002; 12 (6): 558-61
80. Chimenti S, Peris K, Di Cristofaro S, et al. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma. Dermatology 1995; 190 (3): 214-7
81. Edwards L, Tucker SB, Perednia D, et al. The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas. Arch Dermatol 1990; 126 (8): 1029-32
82. Alpsoy E. Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. J Dermatol 1996; 23 (6): 394-6
83. Cornell RC, Greenway HT, Tucker SB, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990; 23 (4 Pt 1): 694-700
84. Tucker SB, Polasek JW, Perri AJ, et al. Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J Am Acad Dermatol 2006; 54 (6): 1033-8
85. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26: 112-21S
86. Stenquist B, Wennberg AM, Gisslen H, et al. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery. J Am Acad Dermatol 1992; 27 (1): 65-9
87. Hurd DS, Conte ET. Practical uses of the interferons in dermatology. Int J Dermatol 1998; 37 (12): 881-96
88. Danenberg PV, Shea LC, Danenberg K. Effect of 5-fluorouracil substitution on the self-splicing activity of Tetrahymena ribosomal RNA. Cancer Res 1990; 50 (6): 1757-63
89. Goette DK. Topical chemotherapy with 5-flurouracil. J Am Acad Dermatol 1981; 4 (6): 633-49
90. Reymann F. Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment: a 10-year follow-up study. Dermatologica 1979; 158 (5): 368-72
91. Epstein E. Fluorouracil paste treatment of thin basal cell carcinomas. Arch Dermatol 1985; 121 (2): 207-13
92. Miller BH, Shavin JS, Cognetta A, et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. J Am Acad Dermatol 1997; 36 (1): 72-7
93. Romagosa R, Saap L, Givens M, et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatol Surg 2000; 26 (4): 338-40
94. Tsuji T, Otake N, Nishimura M. Cryosurgery and topical fluorouracil: a treatment method for widespread basal cell epithelioma in basal cell nevus syndrome. J Dermatol 1993; 20 (8): 507-13
95. Klostermann GF. Effects of 5-fluorouracil (5-FU) ointment on normal and diseased skin: histologic findings and deep action. Dermatologica 1970; 140 Suppl. 1: 47-54
96. Mohs FE, Jones DL, Bloom RF. Tendency of fluorouracil to conceal deep foci of invasive basal cell carcinoma. Arch Dermatol 1978; 114: 1021-2
97. Rozenman Y, Gurewich J, Gotsman MS. Myocardial ischemia induced by topical use of 5-fluorouracil. Int J Cardiol 1995; 49: 282-3
98. Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999; 5: 2006
99. Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. British Association of Dermatologists. Br J Dermatol 1999; 141 (3): 415-23
100. Rodriguez-Cuevas S, Barroso-Bravo S, Almanza-Estrada J, et al. Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin. Arch Med Res 2001; 32 (4): 273-6
101. Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol 1999; 22 (1): 32-4
102. Glass LF, Jaroszeski M, Gilbert R, et al. Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma. J Am Acad Dermatol 1997; 37 (4): 596-9
103. Morley M, Finger PT, Perlin M, et al. Cis-platinum chemotherapy for ocular basal cell carcinoma. Br J Ophthalmol 1991; 75 (7): 407-10
104. Guthrie TH Jr, Porubsky ES, Luxenberg MN, et al. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 1990; 8 (2): 342-6
105. Khandekar JD. Complete response of metastatic basal cell carcinoma to cisplatin chemotherapy: a report on two patients. Arch Dermatol 1990; 126 (12): 1660
106. Baxter DL Jr, Joyce AP, Feldman BD, et al. Cisplatin chemotherapy for basal cell carcinoma: the need for posttreatment biopsy -report of a case. J Am Acad Dermatol 1990; 23 (6 Pt 1): 1167-8
107. Coker DD, Elias EG, Viravathana T, et al. Chemotherapy for metastatic basal cell carcinoma. Arch Dermatol 1983; 119 (1): 44-50
108. Bason MM, Grant-Kels JM, Govil M. Metastatic basal cell carcinoma: response to chemotherapy. J Am Acad Dermatol 1990; 22 (5 Pt 2): 905-8
109. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992; 55 (1): 145-57
110. Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. J Am Acad Dermatol 2000; 42 (3): 389-413
111. Pass HI. Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst 1993; 85 (6): 443-56
112. Engbrecht BW, Menon C, Kachur AV, et al. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model. Cancer Res 1999; 59 (17): 4334-42
113. Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, why and how. Photochem Photobiol Sci 2002; 1 (1): 1-21
114. Gollnick SO, Liu X, Owczarczak B, et al. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res 1997; 57 (18): 3904-9
115. de Vree WJ, Essers MC, de Bruijn HS, et al. Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res 1996; 56 (13): 2908-11
116. Dougherty TJ, Cooper MT, Mang TS. Cutaneous phototoxic occurrences in patients receiving photofrin. Lasers Surg Med 1990; 10 (5): 485-8
117. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004; 5 (8): 497-508
118. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79 (12): 2282-308
119. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998; 90 (12): 889-905
120. Svanberg K, Anderson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical 5-aminolaevulinic acid sensitisation and laser irradiation. Br J Dermatol 1994; 130 (6): 743-51
121. Fritsch C, Lehmann P, Stahl W, et al. Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid. Br J Cancer 1999; 79 (9-10): 1603-8
122. Collaud S, Juzeniene A, Moan J, et al. On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation. Curr Med Chem Anticancer Agents 2004; 4 (3): 301-16
123. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990; 6 (1-2): 143-8
124. Roberts DJH, Cairnduff F. Photodynamic therapy of primary skin cancer: a review. Br J Plast Surg 1995; 48 (6): 360-70
125. Wilson BD, Mang TS, Stoll H, et al. Photodynamic therapy for the treatment of basal cell carcinoma. Arch Dermatol 1992; 128 (12): 1597-601
126. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid: an alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? [Published erratum appears in J Am Acad Dermatol 1993; 29 (1): 41]. J Am Acad Dermatol 1993; 28 (1): 17-21
127. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B 1995; 29 (1): 53-7
128. Fink-Puches R, Soyer HP, Hofer A, et al. Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy. Arch Dermatol 1998; 134: 821-6
129. Peng Q, Warloe T, Berg K, et al. 5-ALA based photodynamic therapy. Cancer 1997; 79 (12): 2282-308
130. Morton CA, Brown SB, Collins S, et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002; 146 (4): 552-67
131. Langmack K, Mehta R, Twyman P, et al. Topical photodynamic therapy at low fluence rates: theory and practice. J Photochem Photobiol B Biol 2001; 60: 37-43
132. Wang I, Bendsoe N, Klinteberg CAF, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144: 832-40
133. Horn M, Wolf P, Wulf HC, et al. Topical methyl aminolevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol 2003; 149 (6): 1242-9
134. Pennington DG, Waner M, Knox A. Photodynamic therapy for multiple skin cancers. Plast Reconstr Surg 1988; 82 (6): 1067-71
135. Cairnduff F, Stringer MR, Hudson EJ, et al. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. Br J Cancer 1994; 69 (3): 605-8
136. Haller JC, Cairnduff F, Slack G, et al. Routine double treatments of superficial basal cell carcinomas using aminolevulinic acid-based photodynamic therapy. Br J Dermatol 2000; 143 (6): 1270-5
137. Soler AM, Warloe T, Tausjo J, et al. Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: a one-year follow-up study. Acta Derm Venereol 1999; 79 (3): 204-6
138. Itoh Y, Henta T, Ninomiya Y, et al. Repeated 5-aminolevulinic acid-based photodynamic therapy following electro-curettage for pigmented basal cell carcinoma. J Dermatol 2000; 27 (1): 10-5
139. Lui H, Salasche S, Kollias N, et al. Photodynamic therapy and nonmelanoma skin cancer with topical aminolevulinc acid: a clinical and histologic study. Arch Dermatol 1995; 131 (6): 737-8
140. Morton CA, MacKie RM, Whitehurst C, et al. Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol 1998; 134 (2): 248-9
141. Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140 (1): 17-23
142. Foley P. Clinical efficacy of methyl aminolevulinate (Metvix) photodynamic therapy. J Dermatolog Treat 2003; 14 Suppl. 3: 15-22
143. Thissen MR, Schroeter CA, Neumann HA. Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol 2000; 142 (2): 338-9
144. Soler AM, Angell-Petersen E, Warloe T, et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: a comparison of two light sources. Photochem Photobiol 2000; 71 (6): 724-9
145. Fijan S, Honigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolevulinic acid and desferrioxamine. Br J Dermatol 1995; 133 (2): 282-8
146. De Rosa FS, Marchetti JM, Thomazini JA, et al. A vehicle for photodynamic therapy of skin cancer: influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. J Control Release 2000; 65 (3): 359-66
147. Uehlinger P, Zellweger M, Wagnieres G, et al. 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J Photochem Photobiol B 2000; 54 (1): 72-80
148. Vinciullo C, Elliott T, Francis D, et al. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. Br J Dermatol 2005; 152 (4): 765-72
149. Wiegell SR, Stender IM, Na R, et al. Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. Arch Dermatol 2003; 139 (9): 1173-7
150. Grapengiesser S, Ericson M, Gudmundsson F, et al. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002; 27 (6): 493-7
151. Dolmans DE, Kadambi A, Hill JS, et al. Vascular accumulation of a novel photosensitizer MV6401 causes selective thrombosis in tumor vessels after photodynamic therapy. Cancer Res 2002; 62 (7): 2151-6
152. Dolmans DE, Kadambi A, Hill JS, et al. Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy. Cancer Res 2002; 62 (15): 4289-94
153. Smith W, Saba N. Retinoids as chemoprevention for head and neck cancer: where do we go from here? Crit Rev Oncol Hematol 2005; 55 (2): 143-52
154. Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N Engl J Med 1999; 341 (23): 1767-8
155. So PL, Lee K, Hebert J, et al. Topical tazarotene chemoprevention reduces basal cell carcinoma number and size in Ptch1+/-mice exposed to ultraviolet or ionizing radiation. Cancer Res 2004; 64 (13): 4385-9
156. Duvic M, Helekar B, Schulz C, et al. Expression of a retinoid-inducible tumor suppressor, tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. Clin Cancer Res 2000; 6 (8): 3249-59
157. Punjabi S, Cook LJ, Kersey P, et al. A double-blind, multicentre parallel group study of BEC-5 cream in basal cell carcinoma. Eur Acad Dermatol Venereol 2000; 14 Suppl. 1: 47-60
158. Wilgus TA, Koki AT, Zweifel BS, et al. Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer. Mol Carcinog 2003; 38 (1): 33-9
159. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19 (5): 723-9
160. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294 (1): 47-55
161. Grau MV, Baron JA, Langholz B, et al. Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer 2006; 119 (3): 682-6
162. Snoeck R. Papillomavirus and treatment. Antiviral Res 2006; 71 (2-3): 181-91. Epub 2006 Jun 23
163. Calista D. Topical 1% cidofovir for the treatment of basal cell carcinoma. Eur J Dermatol 2002; 12 (6): 562-4
164. Cuevas P, Arrazola JM. Treatment of basal cell carcinoma with dobesilate. J Am Acad Dermatol 2005; 53 (3): 526-7
165. Angulo J, Cuevas P, Fernandez A, et al. Calcium dobesilate potentiates endothelium-derived hyperpolarizing factor-mediated relaxation of human penile resistance arteries. Br J Pharmacol 2003; 139 (4): 854-62
166. Tejerina T, Ruiz E. Calcium dobesilate: pharmacology and future approaches. Gen Pharmacol 1998; 31 (3): 357-60
167. Suschek C, Kolb H, Kolb-Bachofen V. Dobesilate enhances endothelial nitric oxide synthase-activity in macro- and microvascular endothelial cells. Br J Pharmacol 1997; 122 (7): 1502-8